<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">Data evaluating the use of systemic corticosteroids in COVID-19 are limited. Recently, the preliminary results of a large randomized controlled trial (RCT) conducted in the United Kingdom revealed reduced 28-day mortality and hospital length of stay in oxygen requiring or ventilated patients treated with dexamethasone 6 mg daily for 10 days as compared with usual care.
 <xref rid="bib14" ref-type="bibr">
  <sup>14</sup>
 </xref> Conversely, data from the SARS and MERS epidemics are conflicting and many studies have revealed no mortality benefit, delayed viral clearance, and evidence for harm.
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib17" ref-type="bibr">17</xref> A similar lack of benefit and potential for harm has been noted in other viral pneumonias, including influenza and respiratory syncytial virus.
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref>
</p>
